ovarian
-
VaxOnco to sponsor phase 1 trial of breast/ovarian cancer therapeutic vaccine
VaxOnco announced that following FDA IND approval, it will sponsor a phase 1 folate receptor alpha-targeted therapeutic vaccine clinical trial in disease-free patients, previously diagnosed with either breast or ovarian cancer at Mayo Clinic. The …
ovarian | 26 July 2011
-
Genentech to present progress in advanced skin, lung and ovarian cancer treatment
Genentech, a member of the Roche Group, announced that data showing new personalized approaches for people with skin and lung cancer, plus new data with Avastin (bevacizumab) in ovarian cancer, will be presented at the 47th Annual Meeting of the Amer…
ovarian | 19 May 2011
-
Collaboration in ovarian cancer
MabCure has signed a collaboration agreement with Catholic University, KU Leuven and University Hospital, UZ Leuven, Belgium, together comprising one of the largest and most reputable medical centers in Europe. The agreement reflects the partie…
ovarian | 06 November 2010
-
MabCure files provisional patent for ovarian cancer antibodies
MabCure announces it has filed a provisional patent application for its ovarian cancer diagnostic antibodies with the US Patent and Trademark Office. The filing was based on positive results of a recent study that showed MabCure’s tumor-specific m…
ovarian | 24 August 2010
-
HealthLinx to Launch Cancer Diagnostic in Singapore
The HealthLinx OvPlex ovarian cancer diagnostic will be released in Singapore in July. Inex has the rights to distribute the diagnostic in Singapore, Thailand, Vietnam, Malaysia, Indonesia and India. The latter plans to use Singapore as the platf…
ovarian | 06 May 2010
-
HealthLinx Confirms Collaborators for Ovarian Cancer Diagnostic Study
HealthLinx has confirmed its collaborators who will work with the company on its second larger OvPlex ovarian cancer diagnostic trial. The trial using 1150 samples will take place in Australia, Singapore and the UK and include: · Professor Lewi…
ovarian | 28 October 2009
-
Curis announces GDC-0449 phase II ovarian cancer trial design
Curis has announced that its collaborator Genentech has indicated that it expects to initiate a Phase II clinical trial of GDC-0449, an orally-administered small molecule Hedgehog antagonist, as a maintenance therapy for ovarian cancer patients in se…
ovarian | 02 September 2008
-
Yale Ovarian Cancer Detection Technology Licensed In China By SurExam
Yale University Office of Cooperative Research said it has granted an exclusive license agreement with the Chinese company SurExam Life Science & Technology (Shenzhen) Co. for the commercialization of the university's blood testing technology for epi…
ovarian | 28 February 2008
-
Ginger Shows Potential as Ovarian Cancer Treatment
Researchers at the University of Michigan Comprehensive Cancer Center, Ann Arbor, are currently investigating ginger as a treatment for ovarian cancer. Ginger is already known to be effective at controlling inflammation, and inflammation contrib…
ovarian | 01 June 2006
